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Abstract
Introduction and Aims—The Rome III classification system treats functional constipation
(FC) and irritable bowel syndrome with constipation (IBS-C) as distinct disorders, but this
distinction appears artificial, and the same drugs are used to treat both. This study’s hypothesis is
that FC and IBS-C defined by Rome III are not distinct entities.
Method—1,100 adults with a primary care visit for constipation and 1,700 age and gender
matched controls from a health maintenance organization completed surveys 12 months apart;
66.2% returned the first questionnaire. Rome III criteria identified 231 with FC and 201 with IBS-
C. The second survey was completed by 195 of the FC and 141 of the IBS-C cohorts. Both
surveys assessed the severity of constipation and IBS, quality of life (QOL), and psychological
distress.
Results—(1) Overlap: If the Rome III requirement that patients meeting criteria for IBS cannot
be diagnosed FC is suspended, 89.5% of IBS-C cases meet criteria for FC and 43.8% of FC
patients fulfill criteria for IBS-C. (2) No qualitative differences between FC and IBS-C: 44.8% of
FC patients report abdominal pain, and paradoxically IBS-C patients have more constipation
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symptoms than FC. (3) Switching between diagnoses: by 12 months, 1/3 of FC transition to IBS-C
and 1/3 of IBS-C change to FC.
Conclusions—Patients identified by Rome III criteria for FC and IBS-C are not distinct groups.
Revisions to the Rome III criteria, possibly including incorporation of physiological tests of transit
and pelvic floor function, are needed.
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Constipation; Irritable bowel; Diagnostic criteria; Symptom-based diagnosis
Introduction
The Rome III classification system for Functional Gastrointestinal Disorders (FGIDs) treats
Functional Constipation (FC) and constipation predominant Irritable Bowel Syndrome (IBS-
C) as distinct disorders, and implies that they have different pathophysiological mechanisms
and therefore would require different treatment approaches1. The basis of FC is thought to
involve delayed transit through the colon and/or failure to relax the pelvic floor muscles
during attempted defecation whereas the pathophysiology of IBS-C is believed to involve a
disorder of brain-gut interaction with a predominant symptom of pain or discomfort2.
When diagnoses of IBS-C or FC are made using the Rome III criteria there is no overlap
because the Rome III criteria specifically exclude assigning a diagnosis of FC to a patient
who fulfills the criteria for IBS-C (see Table 1)1. However, no rationale for this exclusion
was provided by the authors of the Rome I3 or subsequent versions of the Rome criteria, and
some clinicians regard this requirement as artificial. Moreover, it is noteworthy that both
pro-kinetics such as Tegaserod4, Prucalopride5 and chloride channel agonists such as
Lubiprostone6 have been found in clinical trials to be effective for the treatment of both IBS-
C and FC7.
The purpose of this study was to test the hypothesis that FC and IBS-C as defined by the
Rome III criteria are not distinct entities. To test this, we first examined the overlap between
FC and IBS-C that would result if the requirement that no patient meeting criteria for IBS-C
could also be diagnosed with FC were removed. Second, using the published Rome III
criteria which exclude overlap, we classified patients into mutually exclusive categories and
compared the symptom characteristics of FC and IBS-C. Third, we assessed the degree of
switching between these diagnoses that occurs over time; if the disorders are distinct,
subjects should either recover or retain their original diagnosis, whereas if they have
substantially similar etiologies, one might expect subjects to alternate between these
diagnoses. We also investigated patient characteristics that predict switching diagnoses over
a 12-month period.
Methods
This is a secondary analysis of a larger prospective study on risk factors for chronic
constipation and the impact of chronic constipation on quality of life and health care costs.
The study was carried out at Group Health Cooperative of Puget Sound (GHC), which is a
health management organization. Group Health members aged 18 years or older who made
at least one clinic visit to a primary care provider between September 1, 2005 and December
31, 2005, and were enrolled at the GHC for all of the previous 5 years, were screened for
inclusion in the study. Excluded were subjects with a history of gastrointestinal resection
except appendectomy or cholecystectomy, and subjects with any ICD-9CM codes for
gastrointestinal cancer.
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The screening and recruitment algorithm is shown in Figure 1. We first identified 1,100
subjects for screening who had received a clinical diagnosis of constipation (ICD9CM code
569.0X) at a clinical visit between September 1, 2005 and December 31, 2005, and 1,700
age and sex matched subjects who had not received a clinical diagnosis of constipation at
GHC for at least the last 5 years. Matching was accomplished by stratified sampling: Based
on a previous study of the membership of Group Health Cooperative8, we were aware (a)
that approximately 2/3 of patients with a clinical diagnosis of constipation would meet
Rome III criteria for FC, (b) that a substantial number of people who had not consulted
physicians for constipation would nevertheless meet symptom criteria for FC, and (c) that
constipation is more prevalent in women than men and in older versus younger people. We
therefore designed a quota sampling scheme in which we sampled approximately twice as
many controls as we anticipated obtaining for constipated patients in each age stratum
within each sex. There were 1,707 who completed the enrollment questionnaires (66.2%
response rate) of whom 432 met the Rome III criteria for FC or IBS-C, and 336 (77.8%) of
these completed the 12-month survey.
Ethics Approval
The study was approved by the Institutional Review Boards for the Protection of Human
Subjects at both the University of North Carolina at Chapel Hill and the GHC. As granted by
both review boards, informed consent was inferred from completion and return of
questionnaires, and subjects were not required to return a signed consent document. The
cover letter sent with the survey contained all elements of informed consent.
Survey questionnaires
The questionnaires completed by study subjects included the Rome III Diagnostic
Questionnaire modules for functional constipation, IBS, and bloating. The development and
validation of this questionnaire has been previously described9, 10. In addition to a Rome III
diagnosis, these questionnaires were scored for two indices of symptom severity: (1) the
number of constipation symptoms experienced, based on the 6 Rome III FC symptoms (see
Table 1); and (2) the Constipation Severity Scale (CSS), a score calculated as the sum of the
5-point ordinal ratings (0=never, 1=sometimes, 2=often, 3=most of the time, 4=always) for
the six Rome III functional constipation questions. The CSS was previously validated11. The
frequency of abdominal pain or discomfort was assessed by the Rome III question, “In the
last 3 months, how often did you have discomfort or pain anywhere in your abdomen for any
reason?” Response choices were “never”, “less than one day a month”, “one day a month”,
“2-3 days a month”, “one day a week”, “more than one day a week”, and “every day”.
Demographic information such as age, gender, race, ethnicity, marital status, personal
education as well as personal annual income were ascertained at the enrollment survey.
The baseline and follow-up surveys incorporated the SF-12 Health Survey, and the Patient
Assessment of Constipation Quality of Life (PAC-QOL) questionnaire (which measures the
degree of impairment in quality of life due to constipation). The SF-12 is scored for mental
and physical component summary scores12. The PAC-QOL covers 4 dimensions pertaining
to constipation (physical discomfort, worries and concerns, psychosocial discomfort, and
satisfaction), and the results are presented as a total QOL impact score13. The survey also
included the Brief Symptom Inventory (BSI), which provides an overall measure of
psychological distress inferred from symptoms of anxiety, depression and somatization14.
BSI scale scores were adjusted for sex differences by converting them to T-scores before
statistical analysis.
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Statistical analyses utilized SPSS software (version 15.0 for Windows, SPSS Inc., Chicago,
IL). The Chi-square test was used for dichotomous variables, Student’s t-test was used for
continuous variables, and the Mann-Whitney U test was used for ordinal scaled data. A two-
tailed P-value of p< 0.05 was considered significant. Demographic factors that were
significantly different between the groups at baseline were treated as potential confounders,
and were controlled for using an analysis of covariance (ANCOVA).
Results
Overlap between IBS-C and FC at baseline
Two hundred and one patients met the Rome III criteria for IBS-C and 231 met criteria for
FC at baseline. The Rome III diagnostic criteria for FC include the condition that if a subject
fulfills criteria for IBS, they cannot be diagnosed as FC1, yet 180 of the 201 IBS-C patients
would have met criteria for FC if this restriction were not present (Figure 2). Thus, without
this restriction a total of 411 cases would fulfill criteria for FC of whom 43.8% would also
fulfill criteria for IBS-C, and 89.5% of the 201 IBS-C cases would also fulfill the criteria for
FC. The Venn diagram in Figure 2 illustrates this overlap at baseline.
Demographic Differences between FC and IBS-C
Table 2 compares the demographic characteristics of the 231 subjects who fulfilled the
published Rome III criteria for FC (no overlap with IBS-C permitted) and the 201 who
fulfilled the criteria for IBS-C at baseline. FC patients were older and had a higher
educational level; therefore in the subsequent analyses, we adjusted for both of these factors
as potential confounders (except for non-parametric tests of significance).
Symptom and Psychosocial Differences between FC and IBS-C patients
Table 3 describes the baseline bowel symptoms and psychosocial indices of these two
groups. There was a greater frequency of abdominal discomfort or pain among the IBS-C
patients, and this was expected because the diagnostic criteria for IBS require pain and/or
discomfort. However, 44.8% of FC patients also reported experiencing some abdominal pain
or discomfort within the past 3 months (although they did not meet other symptom criteria
for a diagnosis of IBS). Paradoxically, the IBS-C patients had significantly more
constipation symptoms than their FC counterparts and a significantly worse CSS score,
indicating a more severe degree of constipation at baseline. IBS-C subjects also had a
greater impairment on the PAC-QOL, significantly worse psychological distress on the BSI,
and greater impairment in the SF-12 Mental Composite Score.
Switching of diagnoses
Twelve months after they enrolled in the study, 79/195 (40.5%) of those with FC had
recovered and were no longer constipated (i.e. no longer met the FC or IBS-C criteria), and
30/141 (25.5%) of those who had IBS-C at enrollment were no longer constipated (i.e., no
longer met criteria for IBS-C or FC). The proportion who recovered was nearly twice as
great for FC compared to IBS-C (Table 4).
To investigate the tendency to switch diagnoses over time, we excluded patients who
recovered and examined the diagnoses of those who retained symptoms of constipation at 12
months: Approximately one third (36/111) of FC patients switched and met criteria for IBS-
C or IBS-M at 12 months, which was matched by a third (36/109) of IBS-C patients who
switched and met criteria for FC at 12 months follow-up.
Wong et al. Page 4













Differences in baseline characteristics of patients who switched diagnoses
To explore the possible reasons why IBS-C and FC patients switch diagnoses, we compared
the constipation and pain characteristics at baseline of subjects who switched versus those
who retained their original diagnostic labels. Amongst patients with FC at baseline, those
who switched to IBS-C at 12 months reported more frequent abdominal pain or discomfort
at baseline (median of less than 1 day/mo vs. never, p=0.001 by Mann-Whitney U test) as
well as at 12 months (median of 2-3 days/mo vs. never, p<0.001) compared to those who
remained FC patients. Conversely, IBS-C patients who switched to FC had less frequent
abdominal pain or discomfort at baseline (median of 2-3 days/mo vs. 1 day/week, p<0.001),
and at 12 months (median of less than 1 day/mo vs. 1 day/week, p<0.001) as compared with
those who remained IBS-C.
When those who retained their diagnoses for 12 months were compared to those who
switched (Table 5), there was no difference in the number of constipation symptoms at
baseline or in their baseline CSS scores. This was true for both the group who had FC at
baseline and the group with IBS-C at baseline. The PAC-QOL, SF-12, and BSI scores also
failed to predict whether subjects would switch or remain in the same diagnostic category.
Age and education were treated as covariates in these analyses.
Discussion
The Rome criteria were designed as a tool to categorize patients with functional
gastrointestinal diseases into distinct diagnoses based on their presenting symptoms1. Our
study is the first to evaluate in a large population of subjects with constipation, the ability of
the Rome III criteria to achieve this distinction. The data show that the Rome III criteria for
FC and IBS-C does not separate patients into distinct groups. This is shown by the following
observations:
1. Diagnostic overlap – If the artificial requirement that FC and IBS-C cannot be
diagnosed in the same person is suspended, 89.5% of those with IBS-C also meet
criteria for FC, and conversely 43.8% of patients fulfilling criteria for FC also meet
criteria for IBS-C (Figure 2). This implies that IBS-C is a subset of FC.
2. Lack of specificity in symptom profiles – While IBS-C patients report more
frequent pain or discomfort than FC, 44% of patients meeting only FC criteria also
report some pain or discomfort. Moreover, IBS-C patients paradoxically report
more severe constipation than FC patients.
3. Switching diagnostic labels – When patients who recover from constipation are
excluded, approximately 1/3 of patients with each diagnostic label at study
enrollment switch to the other diagnostic label by 12 months follow-up.
Previous investigators have reported a similar overlap in symptoms in population based
samples and have recognized that the “splitting” of functional gastrointestinal disorders into
discrete diagnoses may not be practical. Locke et al15 demonstrated in a population survey
that there is a significant overlap between functional GI symptoms that have been used to
define symptom complexes. Of relevance, they suggested that up to 6.5% of the population
surveyed had an IBS/constipation overlap. In an early study that alluded to the ambiguity in
the definition of constipation, Probert et al showed that the likelihood of having IBS was
significantly increased in those who met the Rome definition of constipation16. However,
none have directly addressed the issue of the precision of the Rome criteria for
distinguishing between the different diagnostic labels assigned to constipated patients,
namely between functional constipation and IBS-C. In our study we showed that at baseline
there was a large overlap between the diagnostic labels of IBS-C and FC, with
approximately 90% of the IBS-C patients fulfilling the diagnostic criteria for FC, and nearly
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half of the FC patients meeting the criteria for IBS-C. This speaks to the fact that while the
Rome III criteria for these two conditions require them to be mutually exclusive, in reality
these criteria are unable to clearly separate IBS-C from FC patients based on the presenting
symptoms.
One of the few longitudinal studies that attempted to determine the stability of FGID
symptoms was a natural history population survey by Halder et al, which describes a high
rate of turnover in the symptom status of patients17. Their data showed that nearly equal
proportions of IBS-C subjects became FC and vice-versa over follow-up. As compared to
Halder’s study, we focused on patients with a clinical diagnosis of constipation, with the
exclusion of any concurrent gastrointestinal organic pathology, rather than relying on a
population incidence. As such, we had much larger subject numbers and data that we believe
can be extrapolated to patients in the clinical setting.
What is also unique about our study is that we investigated patients who had symptoms of
constipation that were severe enough to result in a medical clinic visit, and who received a
clinical diagnosis of constipation from their physician. This contrasts with the studies of
largely healthy subjects in previous publications. We focused on the constipation
characteristics of these patients, and so had detailed data relating to symptom characteristics,
quality of life and other measures which allowed us to test for differences between the FC
and IBS-C patients and the factors that predicted the stability of their diagnoses.
Abdominal pain or discomfort is the hallmark symptom of IBS18, raising the question of
whether this symptom uniquely distinguishes IBS-C from FC. Our data confirm that IBS-C
patients have more frequent pain or discomfort than FC patients and that FC patients who
had more pain at baseline or who developed more abdominal pain or discomfort during the
12 month follow-up period were more likely to switch from a diagnosis of FC to a diagnosis
of IBS-C. However, the symptom of abdominal pain or discomfort lacked specificity for
IBS-C diagnosis: 44% of patients meeting only criteria for FC at baseline had some
abdominal pain or discomfort, and a reduction in the level of abdominal pain or discomfort
was about as likely to occur and to result in a change of diagnosis as compared to an
increase in abdominal pain or discomfort. These observations are consistent with the
hypothesis that the differences between IBS-C and FC in abdominal pain are quantitative but
not qualitative differences, i.e., they only reflect differences in the frequency of pain or
discomfort. Further studies investigating the pathophysiological mechanisms for pain and
discomfort in these two groups are needed.
Psychological distress is another symptom that has been thought to be more closely linked to
IBS than to FC. Our data confirm greater psychological distress in IBS-C compared to FC,
but neither baseline levels of psychological distress nor changes in psychological distress
from baseline to the end of follow-up were significant predictors of changes in diagnosis
from baseline to 12 months follow-up.
A limitation of this study is that we did not measure relevant physiological parameters such
as whole gut transit time, pelvic floor function during defecation, or pain thresholds. It is
possible that these physiological variables could identify pathophysiologically distinct
groups of patients with constipation. The patients in this study were also older than average
for IBS patients in other series although ages were typical for functional constipation. It is
difficult to see how these limitations could affect our conclusion that the Rome III criteria in
their current form do not identify distinct groups of patients with FC and IBS-C.
There are implications on a number of fronts – First, the Rome symptom based diagnoses
are based on the premise that they “breed true” across clinical and population groups and
provide a framework for identifying patients for research and in collecting accurate
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epidemiologic data1. Our findings suggest that a re-definition of the Rome criteria, as they
pertain to patients with constipation, may be needed to avoid confusion in treatment trials
and disease prevalence reporting. Second, there are clinical ramifications. Physicians
seeking to assign a concrete disease label to their patients or base their treatment algorithms
upon making a definitive diagnosis will likely be frustrated as they find their patients
switching between disorders, and will wonder if their diagnosis was accurate in the first
place.
Conclusions
In summary, the overlap in symptoms between IBS-C and FC and the tendency to alternate
between diagnoses suggest that the Rome III criteria for IBS-C and FC may not identify
etiologically distinct groups of patients. FC and IBS-C appear to be conditions that are
quantitatively different, with IBS-C being more severe than FC, but they appear to be
qualitatively similar. Therefore, rather than being separate diagnoses, we proposed that they
are actually part of the same condition, anchored on different ends of the spectrum of
severity.
In trying to define the true differences between FC and IBS-C, we propose that the current
Rome criteria based on symptom definition are inadequate, but we acknowledge that
physiological tests of motility or transit might identify qualitative differences between FC
and IBS-C.
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WHAT IS CURRENT KNOWLEDGE
• Functional Constipation and Irritable Bowel Syndrome are classified as separate
entities by the Rome III criteria.
• In reality, clinicians have found it difficult to differentiate these two conditions
• Several drugs (Lubiprostone, Tegaserod, Linaclotide) have been found to be
effective for both.
WHAT IS NEW HERE
• There is a large overlap between FC and IBS-C, and patients frequently
transition between these diagnoses over time.
• The Rome III criteria for FC and IBS-C do not identify pathophysiologically
distinct groups and may require revision.
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Study enrollment and follow-up flow chart.
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Venn diagram showing overlap between IBS-C and FC when the Rome III requirement that
FC cannot be diagnosed in a patient who meets criteria for IBS is suspended.
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Table 1
Rome III diagnostic criteria for FC and IBS-C
Functional Constipation Irritable Bowel Syndrome (constipation predominant
subtype)
1 Two or more of the following symptoms:
• Straining ≥ 25% of defecations
• Lumpy or hard stools for ≥ 25% defecations
• Sensation of incomplete evacuation for ≥ 25% of
defecations
• Sensation of anorectal obstruction/blockage ≥
25% of defecations
• Manual maneuvers to facilitate ≥ 25% of
defecations
• ≤ 3 defecations per week
2 Loose stools are rarely present without use of laxatives
3 Diagnostic criteria for IBS not met
1 Recurrent abdominal pain/discomfort for ≥ 3 days,
that is associated with ≥ 2 of the following:
• Improvement with defecation
• Onset associated with fewer stools
• Onset associated with harder stools
2 lumpy or hard stools for ≥ 25% of defecation
(defining IBS-C subtype)
Criteria for either FC or IBS-C must be fulfilled for the past 3 months, with onset of symptoms at least 6 months prior to diagnosis.
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Table 2









Age in years 66 76 61 0.001
Female Gender 68% 70% 78% 0.06
Caucasian Race 86% 88% 89% 0.83
Education (college degree or higher) 38% 43% 35% 0.03
Personal Income (≥ $30,000/year) 54.4% 51.5% 53.7% 0.92













Wong et al. Page 14
Table 3







Frequency of abdominal discomfort or pain (median of ordinal scale ratings 0-6) 0 “never” 4 “1 day/wk” <0.001
Number of chronic constipation symptoms (Range 0-6) 3.21 3.76 <0.001
Constipation Severity Scale (Range 0-24) 7.1 9.7 <0.001
PAC-QOL total score (Range 0-4; higher scores =more impact on QOL) 1.07 1.70 <0.001
SF-12 Physical Composite Score (Mean T-score for normal population=50: higher scores = less
impact on QOL)
42.9 41.1 0.17
SF-12 Mental Composite Score (Mean T-score for normal population=50: higher scores = less
impact on QOL)
52.4 48.9 <0.001




p-values were computed after adjusting for age and education
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Table 4
Diagnoses at baseline and 12 months
FC at 12 mo
%(n)




Well at 12 mo
%(n)
FC at baseline (n=195) 38.5% (75) 13.3% (26) 5.1% (10) 40.5% (79)
IBS-C at baseline (n=141) 25.5% (36) 35.5% (50) 16.3% (23) 21.3% (30)
Abbreviations: mo=months, FC=functional constipation; IBS-C=IBS with constipation
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